CMS is running a time-limited GLP-1 demonstration outside the usual Part D payment flow. TOS supports it and still calls it incomplete.
What happened
CMS is running a time-limited demonstration named the Medicare GLP-1 Bridge. The agency says it starts July 1, 2026 and now runs through December 31, 2027, after the planned BALANCE Part D model did not launch in 2027.
Medicare.gov lists three drugs in the program: Foundayo tablets, Wegovy (shot or tablet), and Zepbound in the KwikPen form only. Single-dose Zepbound vials and pens are left out.
People who qualify and already have Part D pay a $50 monthly copay. CMS says those fills sit outside the usual Part D payment path: the yearly deductible is not applied, that $50 does not add to true out-of-pocket (TrOOP) totals, and Extra Help does not reduce the copay.
On June 4, 2026, The Obesity Society sent CMS a letter backing the Bridge while calling it only a first step. TOS asked for wider access to FDA-approved obesity drugs, more nutrition and behavioral coverage, and a fix for TRICARE for Life beneficiaries who are left out.
On The Pen flagged the same CMS and Lilly rollout earlier. That post is an alert only. This brief is rewritten from CMS, Medicare.gov, and the TOS letter.
What it means
A Medicare member who already has Part D can ask a clinician whether they meet the program BMI and condition rules, and whether a listed drug is appropriate. A clinician has to write the prescription and complete prior authorization through CMS's central processor.
The official eligibility page is on Medicare.gov. It is narrower than any weight-loss prescription. People already getting a GLP-1 paid by their Part D plan are excluded. So are people whose GLP-1 is for type 2 diabetes, sleep apnea that is moderate or severe, or fatty liver disease, because those uses may already sit in Part D.
This is a demonstration, not a law change. CMS already moved the end date when BALANCE slipped, so the window can move again.
What it does not mean
This is not a personal recommendation to start, stop, or switch a drug. It is not proof that one GLP-1 is better than another, or better than surgery. It is not coverage of every obesity medicine. It is not a compounding or gray-market pathway. It does not replace a conversation with a clinician or 1-800-MEDICARE about a specific plan.
Sources
- CMS, Medicare GLP-1 Bridge (page updated 2026-07-13)
- Medicare.gov, Weight loss drugs / GLP-1 Bridge eligibility
- The Obesity Society, June 4, 2026 letter to CMS on the Bridge
- On The Pen alert only (not used for facts)
Related guide
Related discussion
GLP-1 Weight Loss Medications forum
Educational information only. Not medical advice. Do not start, stop, or change treatment from this brief.